On January 8, 2025, Aspect Biosystems announced the closing of its $115-million Series B funding round led by Dimension, with participation from existing and new investors including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures and T1D Fund: A Breakthrough T1D Venture. Aspect plans to use the funding to accelerate the company’s development of regenerative medicines targeting metabolic and endocrine diseases and expand its AI-driven bioprinting platform.
Aspect Biosystems, based in Vancouver, Canada, is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases.
Osler, Hoskin & Harcourt LLP advised Aspect Biosystems with a team consisting of Justin Young, David Jamieson, Ian Morrison, Sylvia McLean and Alyn Nanji (Emerging & High Growth Companies) and Martha Martindale, Emma Newbery and Mathew Li (Financial Services).
Key Contact
Partner, Emerging and High Growth Companies, Vancouver
Team
Partner, Emerging and High Growth Companies, Toronto
Associate, Emerging and High Growth Companies, Vancouver
Associate, Emerging and High Growth Companies, Vancouver
Associate, Emerging and High Growth Companies, Toronto
Partner, Financial Services, Vancouver
Associate, Financial Services, Vancouver
Associate, Financial Services, Vancouver
